Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (19)

2024

  1. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition

    Biochemical Pharmacology

2022

  1. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

    Hepatology, Vol. 76, Núm. 5, pp. 1259-1274

2021

  1. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics

    Aging, Vol. 13, Núm. 19, pp. 23416-23434

  2. Novel pharmacological options in the treatment of cholangiocarcinoma: Mechanisms of resistance

    Cancers, Vol. 13, Núm. 10

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

2018

  1. Dysregulation of autophagy in rat liver with mitochondrial DNA depletion induced by the nucleoside analogue zidovudine

    Archives of Toxicology, Vol. 92, Núm. 6, pp. 2109-2118

2015

  1. Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the mother-placenta-foetus trio during cholestasis of pregnancy

    British Journal of Clinical Pharmacology, Vol. 79, Núm. 2, pp. 316-329

2012

  1. Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta

    Molecular Pharmacology, Vol. 81, Núm. 2, pp. 273-283

  2. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs

    Current Cancer Drug Targets, Vol. 12, Núm. 4, pp. 402-438

2011

  1. A homozygous nonsense mutation (c.214C→A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis

    Journal of Medical Genetics, Vol. 48, Núm. 4, pp. 219-225

2010

  1. Strategies for overcoming chemotherapy resistance in enterohepatic tumours

    Current Molecular Medicine, Vol. 10, Núm. 5, pp. 467-485

2009

  1. Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs

    Frontiers in Bioscience, Vol. 14, Núm. 11, pp. 4257-4280

2006

  1. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps

    Biochemical Pharmacology, Vol. 72, Núm. 6, pp. 729-738

  2. Maternal ethanol consumption during pregnancy enhances bile acid-induced oxidative stress and apoptosis in fetal rat liver

    Toxicology, Vol. 225, Núm. 2-3, pp. 183-194

2005

  1. Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis

    Clinical Science, Vol. 109, Núm. 2, pp. 199-207

  2. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis

    Journal of Pharmacology and Experimental Therapeutics, Vol. 312, Núm. 2, pp. 751-758

  3. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid

    Journal of Hepatology, Vol. 43, Núm. 2, pp. 324-332

  4. Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism

    Journal of Pharmacology and Experimental Therapeutics, Vol. 315, Núm. 1, pp. 24-35

2002

  1. Chronic renal failure-induced changes in serum and urine bile acid profiles

    Digestive Diseases and Sciences, Vol. 47, Núm. 11, pp. 2398-2406